$22.8 Billion is the total value of Baker Brothers Advisors's 122 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 18.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seagen Inc. | $8,029,546,000 | +7.6% | 47,288,259 | 0.0% | 35.26% | +7.5% | |
| BGNE | BeiGene, Ltd.sponsored adr | $4,235,810,000 | +5.8% | 11,668,897 | 0.0% | 18.60% | +5.8% | |
| INCY | Buy | Incyte Corporation | $2,202,482,000 | -18.2% | 32,022,125 | +0.0% | 9.67% | -18.2% |
| KOD | Buy | Kodiak Sciences Inc. | $1,409,112,000 | +7.2% | 14,681,304 | +3.8% | 6.19% | +7.2% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $723,886,000 | +55.4% | 4,541,604 | +28.3% | 3.18% | +55.5% |
| ACAD | ACADIA Pharmaceuticals Inc. | $696,137,000 | -31.9% | 41,910,704 | 0.0% | 3.06% | -31.9% | |
| BMRN | Buy | BioMarin Pharmaceutical Inc. | $588,988,000 | -7.0% | 7,620,494 | +0.4% | 2.59% | -7.0% |
| ARGX | argenx SEsponsored adr | $338,106,000 | +0.3% | 1,119,557 | 0.0% | 1.48% | +0.3% | |
| PRLD | Prelude Therapeutics Inc. | $316,370,000 | +9.2% | 10,123,824 | 0.0% | 1.39% | +9.1% | |
| NVTA | Sell | Invitae Corporation | $280,703,000 | -18.8% | 9,873,488 | -3.7% | 1.23% | -18.8% |
| MRTX | Mirati Therapeutics, Inc. | $249,405,000 | +9.5% | 1,409,784 | 0.0% | 1.10% | +9.5% | |
| ABCL | AbCellera Biologics Inc. | $209,422,000 | -8.9% | 10,450,180 | 0.0% | 0.92% | -8.9% | |
| IGMS | IGM Biosciences, Inc. | $207,545,000 | -21.0% | 3,156,102 | 0.0% | 0.91% | -21.0% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $182,654,000 | -9.1% | 12,710,818 | 0.0% | 0.80% | -9.2% | |
| KYMR | Buy | Kymera Therapeutics, Inc. | $140,080,000 | +47.4% | 2,384,742 | +21.7% | 0.62% | +47.5% |
| PACB | Buy | Pacific Biosciences of California, Inc. | $139,119,000 | +24.2% | 5,444,963 | +70.1% | 0.61% | +24.2% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $119,622,000 | -18.1% | 1,499,213 | 0.0% | 0.52% | -18.1% | |
| LEGN | Buy | Legend Biotech Corporationsponsored ads | $119,524,000 | +74.9% | 2,364,003 | +42.0% | 0.52% | +75.0% |
| AMRN | Sell | Amarin Corporation plcsponsored adr | $111,466,000 | -3.8% | 21,856,032 | -17.4% | 0.49% | -3.9% |
| IMCR | Immunocore Holdings plcads | $93,443,000 | -5.1% | 2,520,730 | 0.0% | 0.41% | -5.1% | |
| HRTX | Heron Therapeutics, Inc. | $86,928,000 | -31.1% | 8,131,678 | 0.0% | 0.38% | -31.0% | |
| CERS | Cerus Corporation | $83,513,000 | +3.0% | 13,713,195 | 0.0% | 0.37% | +3.1% | |
| GBT | Global Blood Therapeutics, Inc. | $81,980,000 | -27.2% | 3,217,441 | 0.0% | 0.36% | -27.3% | |
| ALLK | Allakos Inc. | $74,432,000 | +24.0% | 703,050 | 0.0% | 0.33% | +23.9% | |
| NRIX | Nurix Therapeutics, Inc. | $73,524,000 | +12.9% | 2,454,082 | 0.0% | 0.32% | +12.9% | |
| DBVT | DBV Technologies S.A.sponsored adr | $71,610,000 | -10.3% | 14,614,264 | 0.0% | 0.31% | -10.3% | |
| TIL | Instil Bio, Inc. | $69,600,000 | -7.5% | 3,893,700 | 0.0% | 0.31% | -7.3% | |
| VERV | Verve Therapeutics, Inc. | $66,577,000 | -22.0% | 1,416,530 | 0.0% | 0.29% | -22.1% | |
| VSTM | Verastem, Inc. | $66,194,000 | -24.3% | 21,491,630 | 0.0% | 0.29% | -24.2% | |
| HZNP | Horizon Therapeutics Public Ltd Co | $65,627,000 | +17.0% | 599,110 | 0.0% | 0.29% | +17.1% | |
| NBIX | Neurocrine Biosciences, Inc. | $64,929,000 | -1.4% | 676,975 | 0.0% | 0.28% | -1.4% | |
| INSM | Insmed Incorporated | $59,376,000 | -3.2% | 2,156,001 | 0.0% | 0.26% | -3.0% | |
| IMTX | Buy | Immatics N.V. | $57,509,000 | +15.7% | 4,423,731 | +3.3% | 0.25% | +16.1% |
| Buy | Apellis Pharmaceuticals, Inc.note 3.5% 9/15/2026 | $57,262,000 | +106.0% | 46,754,000 | +211.7% | 0.25% | +105.7% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $50,826,000 | +21.4% | 9,830,877 | 0.0% | 0.22% | +21.2% | |
| RYTM | Rhythm Pharmaceuticals, Inc. | $50,454,000 | -33.3% | 3,863,239 | 0.0% | 0.22% | -33.1% | |
| ZYME | Zymeworks Inc. | $49,614,000 | -16.3% | 1,708,472 | 0.0% | 0.22% | -16.2% | |
| TVTX | Buy | Travere Therapeutics, Inc. | $49,464,000 | +1713.9% | 2,039,772 | +991.3% | 0.22% | +1708.3% |
| BLUE | Buy | bluebird bio, Inc. | $47,770,000 | +558.1% | 2,499,715 | +1001.3% | 0.21% | +556.2% |
| TLIS | Talis Biomedical Corporation | $47,343,000 | -43.3% | 7,574,835 | 0.0% | 0.21% | -43.3% | |
| FMTX | Forma Therapeutics Holdings, Inc. | $46,957,000 | -6.8% | 2,024,876 | 0.0% | 0.21% | -6.8% | |
| MRUS | Merus N.V. | $44,824,000 | +4.4% | 2,037,469 | 0.0% | 0.20% | +4.2% | |
| Insmed Incorporatednote 0.75% 6/1/2028 | $43,839,000 | -0.5% | 40,000,000 | 0.0% | 0.19% | -0.5% | ||
| Sarepta Therapeutics, Inc.dbcv 1.5% 11/15/2024 | $43,167,000 | +12.2% | 29,174,000 | 0.0% | 0.19% | +12.4% | ||
| RARE | Ultragenyx Pharmaceutical Inc. | $40,084,000 | -5.4% | 444,444 | 0.0% | 0.18% | -5.4% | |
| ALKS | Alkermes plc | $37,877,000 | +25.8% | 1,228,170 | 0.0% | 0.17% | +25.8% | |
| FLGT | Fulgent Genetics, Inc. | $36,071,000 | -2.5% | 401,016 | 0.0% | 0.16% | -2.5% | |
| AVTE | Buy | Aerovate Therapeutics, Inc. | $34,663,000 | +6.3% | 1,652,171 | +15.7% | 0.15% | +6.3% |
| ALGS | Buy | Aligos Therapeutics, Inc. | $32,205,000 | -1.9% | 2,076,400 | +29.0% | 0.14% | -2.1% |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $31,887,000 | -18.2% | 2,799,577 | 0.0% | 0.14% | -18.1% | |
| KRYS | Krystal Biotech, Inc. | $31,730,000 | -23.2% | 607,735 | 0.0% | 0.14% | -23.2% | |
| Tricida, Inc.note 3.5% 5/15/2027 | $31,375,000 | +14.8% | 75,000,000 | 0.0% | 0.14% | +15.0% | ||
| NLTX | Neoleukin Therapeutics, Inc. | $27,631,000 | -21.7% | 3,821,740 | 0.0% | 0.12% | -21.9% | |
| OPT | Sell | Opthea Limitedsponsored ads | $27,062,000 | -0.1% | 3,382,797 | -0.9% | 0.12% | 0.0% |
| AGLE | Aeglea BioTherapeutics, Inc. | $27,110,000 | +14.2% | 3,410,106 | 0.0% | 0.12% | +14.4% | |
| KDNY | Buy | Chinook Therapeutics, Inc. | $24,283,000 | +59.2% | 1,903,069 | +76.1% | 0.11% | +59.7% |
| BCAB | BioAtla, Inc. | $24,288,000 | -30.5% | 825,000 | 0.0% | 0.11% | -30.5% | |
| NVAX | Sell | Novavax, Inc. | $22,546,000 | -26.1% | 108,756 | -24.3% | 0.10% | -26.1% |
| RETA | Reata Pharmaceuticals, Inc.cl a | $22,534,000 | -28.9% | 223,976 | 0.0% | 0.10% | -28.8% | |
| BCEL | Atreca, Inc. | $22,009,000 | -26.9% | 3,532,760 | 0.0% | 0.10% | -26.5% | |
| DSGN | Design Therapeutics, Inc. | $21,104,000 | -26.1% | 1,436,636 | 0.0% | 0.09% | -25.6% | |
| ACHL | Achilles Therapeutics plcsponsored ads | $20,187,000 | -20.4% | 2,591,366 | 0.0% | 0.09% | -19.8% | |
| New | DICE Therapeutics, Inc. | $19,265,000 | – | 588,235 | +100.0% | 0.08% | – | |
| CRNX | Crinetics Pharmaceuticals, Inc. | $19,380,000 | +11.7% | 920,656 | 0.0% | 0.08% | +11.8% | |
| CNTA | Buy | Centessa Pharmaceuticals plcsponsored ads | $18,825,000 | +111.9% | 1,127,273 | +181.8% | 0.08% | +112.8% |
| New | Surrozen, Inc. | $17,700,000 | – | 2,500,000 | +100.0% | 0.08% | – | |
| AXSM | Axsome Therapeutics, Inc. | $17,767,000 | -51.1% | 539,057 | 0.0% | 0.08% | -51.2% | |
| OTIC | Buy | Otonomy, Inc. | $14,773,000 | -8.3% | 7,694,038 | +6.5% | 0.06% | -8.5% |
| CYT | Cyteir Therapeutics, Inc. | $14,262,000 | -18.0% | 812,640 | 0.0% | 0.06% | -17.1% | |
| ALBO | Albireo Pharma, Inc. | $12,869,000 | -11.3% | 412,466 | 0.0% | 0.06% | -10.9% | |
| MIRM | Mirum Pharmaceuticals, Inc. | $12,894,000 | +15.2% | 647,313 | 0.0% | 0.06% | +16.3% | |
| Invitae Corporationnote 2.0% 9/1/2024 | $12,570,000 | -9.5% | 10,300,000 | 0.0% | 0.06% | -9.8% | ||
| ALT | Altimmune, Inc. | $12,125,000 | +14.8% | 1,072,038 | 0.0% | 0.05% | +15.2% | |
| New | Tscan Therapeutics, Inc. | $11,885,000 | – | 1,425,000 | +100.0% | 0.05% | – | |
| AUPH | Sell | Aurinia Pharmaceuticals Inc. | $11,519,000 | -20.6% | 520,523 | -53.5% | 0.05% | -20.3% |
| ANAB | AnaptysBio, Inc. | $11,585,000 | +4.6% | 427,179 | 0.0% | 0.05% | +4.1% | |
| XENE | Xenon Pharmaceuticals Inc. | $11,485,000 | -17.9% | 751,639 | 0.0% | 0.05% | -18.0% | |
| New | Tango Therapeutics, Inc. | $9,698,000 | – | 750,000 | +100.0% | 0.04% | – | |
| MGNX | Buy | MacroGenics, Inc. | $9,268,000 | +71.9% | 442,579 | +120.5% | 0.04% | +70.8% |
| KRTX | Karuna Therapeutics, Inc. | $8,559,000 | +7.3% | 69,966 | 0.0% | 0.04% | +8.6% | |
| EWTX | Edgewise Therapeutics, Inc. | $8,300,000 | -22.2% | 500,000 | 0.0% | 0.04% | -23.4% | |
| CABA | Buy | Cabaletta Bio, Inc. | $8,051,000 | +47.1% | 662,063 | +4.0% | 0.04% | +45.8% |
| CBAY | Cymabay Therapeutics, Inc. | $7,922,000 | -16.3% | 2,170,464 | 0.0% | 0.04% | -16.7% | |
| ATHA | Athira Pharma, Inc. | $7,564,000 | -8.4% | 806,367 | 0.0% | 0.03% | -8.3% | |
| BMEA | Buy | Biomea Fusion, Inc. | $6,280,000 | +36.8% | 524,617 | +78.4% | 0.03% | +40.0% |
| GTH | Genetron Holdings Limitedads | $6,306,000 | -31.2% | 455,306 | 0.0% | 0.03% | -30.0% | |
| AMYT | New | Amryt Pharma plcsponsored adr | $6,244,000 | – | 518,380 | +100.0% | 0.03% | – |
| NGM | NGM Biopharmaceuticals, Inc. | $6,134,000 | +6.6% | 291,801 | 0.0% | 0.03% | +8.0% | |
| RVMD | Revolution Medicines, Inc. | $6,113,000 | -13.3% | 222,222 | 0.0% | 0.03% | -12.9% | |
| LIFE | New | aTyr Pharma, Inc. | $5,675,000 | – | 625,000 | +100.0% | 0.02% | – |
| KURA | New | Kura Oncology, Inc. | $5,697,000 | – | 304,158 | +100.0% | 0.02% | – |
| ALEC | Alector, Inc. | $5,459,000 | +9.6% | 239,228 | 0.0% | 0.02% | +9.1% | |
| CCXI | New | ChemoCentryx, Inc. | $5,150,000 | – | 301,195 | +100.0% | 0.02% | – |
| RLMD | Buy | Relmada Therapeutics, Inc. | $5,268,000 | +114.8% | 200,996 | +162.4% | 0.02% | +109.1% |
| TCDA | Buy | Tricida, Inc. | $4,814,000 | +52.8% | 1,037,432 | +42.3% | 0.02% | +50.0% |
| HRMY | Harmony Biosciences Holdings, Inc. | $4,738,000 | +35.8% | 123,600 | 0.0% | 0.02% | +40.0% | |
| Sell | BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $4,611,000 | -70.4% | 4,500,000 | -70.0% | 0.02% | -70.6% | |
| DNLI | Denali Therapeutics Inc. | $4,477,000 | -35.7% | 88,738 | 0.0% | 0.02% | -35.5% | |
| REPL | Replimune Group, Inc. | $4,550,000 | -22.9% | 153,512 | 0.0% | 0.02% | -23.1% | |
| NEXI | NexImmune, Inc. | $4,453,000 | -7.2% | 294,117 | 0.0% | 0.02% | -4.8% | |
| ITOS | Iteos Therapeutics, Inc. | $4,059,000 | +5.3% | 150,346 | 0.0% | 0.02% | +5.9% | |
| HOOK | HOOKIPA Pharma Inc. | $4,126,000 | -35.7% | 700,481 | 0.0% | 0.02% | -35.7% | |
| XLRN | Acceleron Pharma Inc. | $3,860,000 | +37.1% | 22,430 | 0.0% | 0.02% | +41.7% | |
| VINC | New | Vincerx Pharma, Inc. | $3,903,000 | – | 241,379 | +100.0% | 0.02% | – |
| BNR | Burning Rock Biotech Limitedsponsored ads | $3,739,000 | -39.3% | 209,131 | 0.0% | 0.02% | -40.7% | |
| AKRO | Akero Therapeutics, Inc. | $2,646,000 | -9.9% | 118,378 | 0.0% | 0.01% | -7.7% | |
| GMDA | Gamida Cell Ltd. | $2,394,000 | -38.8% | 610,626 | 0.0% | 0.01% | -35.3% | |
| New | Sera Prognostics, Inc. | $2,239,000 | – | 201,562 | +100.0% | 0.01% | – | |
| LPTX | Leap Therapeutics, Inc. | $2,244,000 | +144.4% | 559,705 | 0.0% | 0.01% | +150.0% | |
| EVFM | Evofem Biosciences, Inc. | $1,992,000 | -34.6% | 2,697,110 | 0.0% | 0.01% | -30.8% | |
| SNDX | New | Syndax Pharmaceuticals, Inc. | $2,116,000 | – | 110,729 | +100.0% | 0.01% | – |
| LOGC | LogicBio Therapeutics, Inc. | $2,068,000 | +3.1% | 451,478 | 0.0% | 0.01% | 0.0% | |
| TCRR | TCR2 Therapeutics Inc. | $1,502,000 | -48.1% | 176,461 | 0.0% | 0.01% | -46.2% | |
| TARA | Protara Therapeutics, Inc. | $1,382,000 | -28.9% | 199,671 | 0.0% | 0.01% | -33.3% | |
| KZR | Kezar Life Sciences, Inc. | $1,207,000 | +59.2% | 139,676 | 0.0% | 0.01% | +66.7% | |
| INZY | Inozyme Pharma, Inc. | $1,240,000 | -32.0% | 106,999 | 0.0% | 0.01% | -37.5% | |
| PASG | Passage Bio, Inc. | $1,167,000 | -24.8% | 117,161 | 0.0% | 0.01% | -28.6% | |
| New | Surrozen, Inc.w exp 8/11/2026 | $950,000 | – | 833,333 | +100.0% | 0.00% | – | |
| AFMD | Affimed N.V. | $1,017,000 | -27.3% | 164,605 | 0.0% | 0.00% | -33.3% | |
| Bellicum Pharmaceuticals, Inc. | $727,000 | -11.6% | 249,123 | 0.0% | 0.00% | -25.0% | ||
| OYST | Oyster Point Pharma, Inc. | $728,000 | -31.1% | 61,424 | 0.0% | 0.00% | -40.0% | |
| MREO | Sell | Mereo BioPharma Group plcads | $708,000 | -90.9% | 292,692 | -88.1% | 0.00% | -91.2% |
| SYRS | Exit | Syros Pharmaceuticals, Inc. | $0 | – | -65,497 | -100.0% | -0.00% | – |
| FREQ | Exit | Frequency Therapeutics, Inc. | $0 | – | -55,555 | -100.0% | -0.00% | – |
| ORTX | Exit | Orchard Therapeutics plcads | $0 | – | -1,192,003 | -100.0% | -0.02% | – |
| CHMA | Exit | Chiasma, Inc. | $0 | – | -1,420,740 | -100.0% | -0.03% | – |
| SBTX | Exit | Silverback Therapeutics, Inc. | $0 | – | -238,095 | -100.0% | -0.03% | – |
| ASMB | Exit | Assembly Biosciences, Inc. | $0 | – | -2,108,621 | -100.0% | -0.04% | – |
| ISEE | Exit | IVERIC bio, Inc. | $0 | – | -1,406,037 | -100.0% | -0.04% | – |
| PTGX | Exit | Protagonist Therapeutics, Inc. | $0 | – | -455,276 | -100.0% | -0.09% | – |
| ADCT | Exit | ADC Therapeutics SA | $0 | – | -1,418,107 | -100.0% | -0.15% | – |
| APLS | Exit | Apellis Pharmaceuticals, Inc. | $0 | – | -2,271,917 | -100.0% | -0.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
| 4 | 2024-03-28 |
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-14 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.